- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 17.03. | EXTRAWELL PHAR (00858): COMPLETION OF DISCLOSEABLE TRANSACTION AND CONNECTED TRANSACTION AT SUBSIDIARY LEVEL IN RELATION TO A SHARE BUY-BACK TRANSACTION ... | - | HKEx | ||
| 27.02. | EXTRAWELL PHAR (00858): (1) EXTENSION OF LONG STOP DATE IN RESPECT OF PROPOSED FOURTH AMENDMENTS TO THE TERMS AND CONDITIONS OF THE BONDS (2) DELAY IN ... | - | HKEx | ||
| 20.01. | EXTRAWELL PHAR (00858): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | 2 | HKEx | ||
| 20.01. | EXTRAWELL PHAR (00858): CHANGE OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND CHANGES IN COMPOSITION OF BOARD COMMITTEES | 1 | HKEx | ||
| 31.12.25 | EXTRAWELL PHAR (00858): CHANGE OF BUILDING NAME OF HEAD OFFICE AND PRINCIPAL PLACE OF BUSINESS IN HONG KONG | 2 | HKEx | ||
| 30.12.25 | EXTRAWELL PHAR (00858): DISCLOSEABLE TRANSACTION AND CONNECTED TRANSACTION AT SUBSIDIARY LEVEL IN RELATION TO A SHARE BUY-BACK TRANSACTION OF A NON-WHOLLY ... | 3 | HKEx | ||
| 30.12.25 | EXTRAWELL PHAR (00858): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | - | HKEx | ||
| EXTRAWELL PHARMACEUTICAL Aktie jetzt für 0€ handeln | |||||
| 30.12.25 | EXTRAWELL PHAR (00858): CHANGE OF CHIEF EXECUTIVE OFFICER | 3 | HKEx | ||
| 22.12.25 | EXTRAWELL PHAR (00858): NOTIFICATION LETTER AND REQUEST FORM TO NON-REGISTERED SHAREHOLDERS - NOTICE OF PUBLICATION OF INTERIM REPORT 2025/26 | 2 | HKEx | ||
| 22.12.25 | EXTRAWELL PHAR (00858): NOTIFICATION LETTER AND REPLY FORM TO REGISTERED SHAREHOLDERS - NOTICE OF PUBLICATION OF INTERIM REPORT 2025/26 | 2 | HKEx | ||
| 22.12.25 | EXTRAWELL PHAR (00858): INTERIM REPORT 2025/26 | 1 | HKEx | ||
| 19.12.25 | EXTRAWELL PHAR (00858): GRANT OF SHARE OPTIONS | 2 | HKEx | ||
| 02.12.25 | EXTRAWELL PHAR (00858): MAJOR TRANSACTION - PROPOSED FOURTH AMENDMENTS TO THE TERMS AND CONDITIONS OF THE BONDS | - | HKEx | ||
| 28.11.25 | EXTRAWELL PHAR (00858): INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2025 | 1 | HKEx | ||
| 20.11.25 | EXTRAWELL PHAR (00858): PROFIT WARNING | 2 | HKEx | ||
| 13.11.25 | EXTRAWELL PHAR (00858): DATE OF BOARD MEETING | 1 | HKEx |
16 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| IONIS PHARMACEUTICALS | 59,02 | -1,89 % | BofA bekräftigt 'Buy'-Rating für Ionis nach Preisfestsetzung für Tryngolza | ||
| CSPC PHARMA | 0,934 | +1,52 % | CSPC PHARMA (01093): VOLUNTARY ANNOUNCEMENT - ADOPTION OF THE 2026 SHARE AWARD SCHEME | ||
| SELLAS LIFE SCIENCES | 4,650 | +7,02 % | SELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Reports Full Year 2025 Financial Results and Provides Corporate Update | - Continued Advancement of Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) - Final Analysis upon Reaching 80 Events - - First Patient Dosed in Phase 2 Trial of... ► Artikel lesen | |
| CATALYST PHARMACEUTICALS | 20,340 | +2,16 % | CATALYST PHARMACEUTICALS, INC. - 8-K, Current Report | ||
| ACADIA PHARMACEUTICALS | 19,155 | +5,86 % | Acadia Pharma upgraded at BofA following stock pullback | ||
| MADRIGAL PHARMACEUTICALS | 404,60 | +5,83 % | Madrigal Pharmaceuticals, Inc.: Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) | ||
| ENZON PHARMACEUTICALS | 0,001 | -98,98 % | Enzon Pharmaceuticals, Inc: Enzon Announces Reverse Stock Split | CRANFORD, N.J., March 24, 2026 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (OTCQB: ENZN) ("Enzon" or the "Company"), today announced that the previously approved 1-for-100 reverse stock split... ► Artikel lesen | |
| OPUS GENETICS | 3,815 | -1,93 % | Opus Genetics, Inc.: Opus Genetics Named to Fast Company's Annual List of the World's Most Innovative Companies of 2026 | ||
| ELITE PHARMACEUTICALS | - | - | Elite Pharmaceuticals, Inc.: Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2026 (three months ended December 31, 2025) and Provides Conference Call Information | Northvale, New Jersey--(Newsfile Corp. - February 17, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products... ► Artikel lesen | |
| SAVARA | 4,480 | +2,75 % | Savara Inc.: Savara Announces European Patent Office (EPO) Intends to Grant a Patent for the Liquid Formulation of MOLBREEVI* | -- Once Granted, the Patent Will Provide Protection for MOLBREEVI in Europe Until March 2041 -- -- Savara Was Also Recently Granted a European Patent Covering the Investigational Drug-Device... ► Artikel lesen | |
| GALECTIN THERAPEUTICS | 2,420 | 0,00 % | Galectin Therapeutics Inc.: Galectin Therapeutics Strengthens Board of Directors with Appointment of Henry Brem, M.D. | NORCROSS, Ga., March 17, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of galectin-3-targeted therapeutics for patients with MASH cirrhosis and portal hypertension... ► Artikel lesen | |
| BIODEXA PHARMACEUTICALS | 0,720 | +7,82 % | Biodexa Pharmaceuticals PLC: ADR Ratio Change | March 18, 2026 Biodexa Pharmaceuticals PLC("Biodexa" or the "Company") ADR Ratio Change Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline... ► Artikel lesen | |
| NOVABAY PHARMACEUTICALS | 1,450 | -5,84 % | NovaBay Pharmaceuticals, Inc.: NovaBay Pharmaceuticals Announces Name Change to Stablecoin Development Corporation, Reports Initial Staking Rewards, and Provides SKY Token Holdings Update | Following $134 million investment from R01 Fund LP, Framework Ventures, Tether Investments, S.A. de C.V., and Sky Frontier Foundation, Stablecoin Development Corporation has acquired 2.06 billion... ► Artikel lesen | |
| CIPHER PHARMACEUTICALS | 10,000 | -2,91 % | Cipher Pharmaceuticals übertrifft Gewinnerwartungen, verfehlt aber Umsatzziel | ||
| NEURIZON THERAPEUTICS | 0,038 | -2,56 % | NEURIZON THERAPEUTICS LIMITED: Notification of Expiry of NUZOA Listed Options |
EXTRAWELL PHARMACEUTICAL HOLDINGS LTD gehört der Branche Pharma an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu EXTRAWELL PHARMACEUTICAL HOLDINGS LTD finden Sie auf Wallstreet Online.